Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport dose-ranging study for lateral canthal lines
NCT00247559Phase 2Completed
- Sponsor
- Ipsen
- Start
- May 2004
- Primary completion
- Apr 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of abobotulinumtoxinA in lateral canthal rhytides (4 arms), sponsored by Ipsen. Primary endpoint: Change in severity of crow's feet at maximum smile at 4 weeks. Started May 2004; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT00247559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00247559.